The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough

PURPOSE: We evaluated gefapixant, a P2X3 receptor antagonist, in participants with recent-onset (≤ 12 months) refractory chronic cough (RCC) or unexplained chronic cough (UCC). METHODS: Participants (≥ 18 years of age; ≥ 40 mm on a 100-mm cough severity visual analog scale [VAS] at screening and ran...

Descripción completa

Detalles Bibliográficos
Autores principales: McGarvey, Lorcan, Sher, Mandel, Shvarts, Yury Grigorievich, Lu, Susan, Wu, Wen-Chi, Xu, Ping, Schelfhout, Jonathan, La Rosa, Carmen, Nguyen, Allison Martin, Reyfman, Paul A., Afzal, Amna Sadaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Cough
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115701/
https://www.ncbi.nlm.nih.gov/pubmed/36879087
http://dx.doi.org/10.1007/s00408-023-00606-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115701/
https://www.ncbi.nlm.nih.gov/pubmed/36879087
http://dx.doi.org/10.1007/s00408-023-00606-w

Ejemplares similares